Skip to main contentSkip to navigationSkip to search
Curasight

2021

Curasight A/S presents at Nordnet Live - Spotlight Small Cap investor conference 15 April 2021

April 9, 2021
 | Regulatory
Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans, at the Nordnet Live platform 15 April 2021, 16:20 (CET). The presentation will be webcasted live.

CAD patent application 2,905,172 relating to uTREAT[®] is accepted for grant

March 28, 2021
 | Regulatory
The Canadian Intellectual Property Office has issued a notice of allowance confirming that the Canadian Patent Application no. 14/399,820 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted. The patent will expire May 2033.

Minutes from the Annual General Meeting in Curasight A/S

March 25, 2021
 | Regulatory
Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held its Annual General Meeting on 25 March 2021 at 10:00 (CET) at the Company’s premises, Ole Maaløes Vej 3, room M4, DK-2200 Copenhagen N, Denmark.

Curasight’s presentation at Økonomisk Ugebrev Life Science Investor Conference is now available

March 11, 2021
 | Regulatory
Curasigt A/S by CEO Ulrich Krasilnikoff presented at Økonomisk Ugebrev’s Life Science Investor Conference yesterday. Due to the Covid-19 restrictions the presentation was recorded and is now available here (https://vimeo.com/522230710/35335a2951) (in Danish only).

Notice of Annual General Meeting

March 11, 2021
 | Regulatory
Copenhagen, Denmark, 11 March 2021 – Notice is hereby given of the annual general meeting of Curasight A/S (“Curasight” or the “Company”) to be held on:
Thursday, 25 March 2021 at 10:00 am CET

Due to the COVID-19 situation, the annual general meeting will be held as a completely electronic meeting without physical attendance. This is in accordance with Executive Order no. 2240 of 29 December 2020, which allows companies to conduct fully electronic general meetings even though this has not been approved in advance by the shareholders and stated in the Company’s Articles of Association. More information on how to participate in the annual general meeting can be found below in the section named “practical information”.

Curasight A/S presents at Økonomisk Ugebrev Life Science Investor Conference

March 5, 2021
 | Regulatory
Curasight A/S CEO Ulrich Krasilnikoff will present the company and its future plans, at Økonomisk Ugebrev Life Science Investor Conference 10 March 2021. The presentation will be webcasted live.

Article from Phase II study in prostate cancer now published in the March issue of Journal of Nuclear Medicine and highlighted as best clinical investigation article

February 26, 2021
 | Regulatory
As previously communicated in December 2020, results from the investigator-initiated phase II study performed by researchers at Rigshospitalet were available in 2020. Now, these results are published in the March 2021 issue of the Journal of Nuclear Medicine, which is the most recognized scientific journal in the field of nuclear medicine (highest impact factor). Furthermore, the article (available here) (https://jnm.snmjournals.org/content/62/3/354) has been selected as Featured Clinical Investigation Article of the March issue.

Annual Report for the fiscal year 2020

February 24, 2021
 | Regulatory
Curasight A/S (“Curasight” or “the Company”) hereby publishes the Annual Report for the fiscal year 2020. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Year-end report October – December 2020

February 24, 2021
 | Regulatory
Curasight A/S (“Curasight” or “the Company”) hereby publishes the year-end report for the period October 1 – December 31, 2020. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

US patent application 14/399,820 relating to uTREAT[®] is accepted for grant

February 8, 2021
 | Regulatory
The United States Patent and Trademark Office has issued a notice of allowance confirming that the United States Patent Application no. 14/399,820 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted. The patent will expire May 2033.
Load more